Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium.
Nasreddine, Rakan; Yombi, Jean Cyr; Darcis, Gilleset al.
[en] [en] OBJECTIVES: A paradigm shift from three-drug regimens to two-drug regimens (2DRs) is currently taking place in real-world clinical practice. This study aimed to describe the efficacy, durability, and tolerability of dolutegravir (DTG)/lamivudine (3TC) and DTG/rilpivirine (RPV) in a real-world setting.
METHODS: This was a retrospective, observational, multicentre (ten centres in Belgium) study involving adult treatment-naïve and treatment-experienced people living with HIV on DTG/3TC or DTG/RPV between 1 January 2019 and 30 September 2020. The primary endpoint was rate of virological suppression (VS; plasma HIV-1 viral load [VL] <50 copies/ml) using an on-treatment analysis. Main secondary endpoints included the proportion of people that experienced loss of VS (LVS; defined as two consecutive HIV-1 VLs of >200 copies/ml after initially achieving VS) and a resistance analysis at the time of LVS; rate, incidence, and reasons for discontinuation of treatment (stopping treatment or changing any component of the 2DR); and change in weight, along with the proportion of people reporting a >10% weight gain. Ordinal logistic regression analysis examined associations between baseline variables and >10% on-treatment weight gain.
RESULTS: Overall, 948 people were included, of whom 734 (77%) were on DTG/3TC and 214 (23%) were on DTG/RPV. Baseline characteristics included 54% aged ≥50 years, 31% female, 31% Black sub-Saharan African, 95% treatment-experienced, and 8% with HIV-1 VL ≥50 copies/ml. Through 48 weeks, the rate of VS for the overall cohort was 98.3% (99.1% with 3TC; 96.2% with RPV). LVS was observed in 0.5% (n = 5) of the overall population (n = 1 [3TC group], n = 4 [RPV group]). There were 40 treatment discontinuations (4.2%, n = 27 [3TC group]; n = 13 [RPV group]), corresponding to an incidence of 4.7 per 100 patient-years. The most common reason for discontinuation was an adverse event (1.4%), with neurotoxicity the most frequent (0.5%). Median on-treatment weight gain at week 48 was 1 kg (interquartile range [IQR] -1-3) overall, 1 kg (IQR -1-3) in the 3TC group, and 2 kg (IQR 0-4) in the RPV group. A >10% weight increase was observed in 6.3% of people. Regression analysis showed that being on a tenofovir disoproxil fumarate-based regimen prior to 2DR initiation was the only variable associated with a >10% increase in weight from baseline (odds ratio 3.48; 95% confidence interval 1.13-10.68; p = 0.038).
CONCLUSION: In this real-world analysis, the 2DRs analysed were effective, durable, and safe for those who were treatment-naive and treatment-experienced. A slight increase in weight was associated with these regimens.
Disciplines :
Immunology & infectious disease
Author, co-author :
Nasreddine, Rakan ; Saint-Pierre University Hospital, Brussels, Belgium
Yombi, Jean Cyr; Cliniques Universitaires Saint-Luc, Brussels, Belgium
Darcis, Gilles ; Université de Liège - ULiège > Département des sciences de la santé publique
Florence, Eric; Institute of Tropical Medicine, Antwerp, Belgium
Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium.
Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Accessed September 6, 2021. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf
European AIDS Clinical Society. Guidelines version 11, October 2021. Accessed November 2, 2021. https://www.eacsociety.org/files/guidelines-10.1_finaljan2021_1.pdf
Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the international antiviral society-USA panel. JAMA. 2020;324:1651-1669.
World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidance, 2018. Accessed November 2, 2021. https://www.who.int/hiv/pub/guidelines/ARV2018update/en
Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019;393(10167):143-155.
Wyk JV, Ajana F, Bisshop F, et al. Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen in maintaining virologic suppression through 48 weeks (TANGO study, Oral Presentation). Presented at the 10th International AIDS Society Conference on HIV Science, July 2019, Mexico City, Mexico.
Llibre JM, Hung C-C, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 2018;391(10123):839-849.
Sutton S, Magagnoli J, Hardin J. Odds of viral suppression by single-tablet regimens, multiple tablet regimens, an adherence level in HIV/AIDS patients receiving antiretroviral therapy. Pharmacotherapy. 2017;37(2):204-213.
Parienti J, Barrail-Tran A, Duval X, et al. Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial. Antimicrob Agents Chemother. 2013;57(5):2265-2271.
Sciensano. Epidémiologie du sida et de l'infection à VIH en Belgique: situation au 31 décembre 2020. Accessed September 8, 2021. https://www.sciensano.be/en/biblio/epidemiologie-du-sida-et-de-linfection-a-vih-en-belgique-situation-au-31-decembre-2020
United Nations Statistics Division. Composition of macro geographical (continental) regions, geographical sub-regions, and selected economic other groupings. Accessed June 22, 2021. https://unstats.un.org/unsd/mi/africa.htm
Taiwo BO, Marconi VC, Berzins B, et al. Dolutegravir plus lamivudine maintains human immunodeficiency Virus-1 suppression through week 48 in a pilot randomized trial. Clin Infect Dis. 2018;66(11):1794-1797.
Noe S, Ummard-Berger K, Hillenbrand H, et al. 12-month outcome of Dolutegravir/Rilpivirine in virologically suppressed HIV-infected patients:real-world data from the German JUNGLE cohort (poster). Presented at HIV Drug Therapy 2020, October 2020, Virtual.
Capetti AF, Sterrantino G, Cossu MV, et al. Switch to Dolutegravir plus Rilpivirine dual therapy in cART-experienced subjects: an observational cohort. PLoS One. 2016;11(10):e0164753.
Maggiolo F, Gulminetti R, Pagnucco L, et al. Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients. BMC Infect Dis. 2017;17(1):215.
Joly V, Burdet C, Landman R, et al. Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL). J Antimicrob Chemother. 2019;74(3):739-745.
Hidalgo-Tenorio C, Cortés LL, Gutiérrez A, et al. DOLAMA study: effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients. Medicine (Baltimore). 2019 Aug;98(32):e16813.
Galizzi N, Poli A, Galli L, et al. Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients. Int J Antimicrob Agents. 2020;55:105893.
Deschanvres C, Raffi F, Reynes J, et al. Virologic failure and resistance in dolutegravir-based maintenance dual regimens. (poster). Presented at the Conference on Retroviruses and Opportunistic Infections 2020, March 2020, Boston, MA.
Gagliardini R, Lorenzini P, Cozzi-Lepri A, et al. Effect of past virological failure on dolutegravir+lamivudine as maintenance regimen (poster). Presented at the Conference on Retroviruses and Opportunistic Infections 2020, March 2020, Boston, MA.
Diaz A, Casado JL, Dronda F et al. Dolutegravir plus rilpivirine in suppressed heavily pre-treated HIV-infected patients [abstract tupdb0 106]. Presented at the 21st International AIDS Conference, July 2016, Durban, South Africa.
Garcia-Gasco P, Maida I, Blanco F, et al. Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. J Antimicrob Chemother. 2008;61(3):699-704.
Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. Jama. 2005;293(7):817-829.
Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hannaet GJ, et al. Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia. J Infect Dis. 2007;196(12):1773-1778.
Grennan JT, Loutfy MR, Su D, et al. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis. 2012;205(8):1230-1238.
Sorstedt E, Nilsson S, Blaxhult A, et al. Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels. BMC Infect Dis. 2016;16:305.
Cohen Stuart JW, Wensing AM, Kovacs C, et al. Transient relapses (“blips”) of plasma HIV RNA levels during HAART are associated with drug resistance. J Acquir Immune Defic Syndr. 2001;28(2):105-113.
Macias J, Palomares JC, Mira JA, et al. Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy. J Infect. 2005;51(3):195-200.
Baldin G, Ciccullo A, Rusconi S, et al. Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicenter cohort of HIV-1-infected, virologically suppressed patients. Int J Antimicrob Agents. 2019;54:728-734.
Maggiolo F, Comi L, Gulminetti R, et al. Dolutegravir? Lamivudine in patients with suppressed HIV-RNA: long term virologic and immunologic results of a multicenter cohort (poster). Presented at HIV Drug Therapy Glasgow 2018, October 2018, Glasgow, Scotland.
Bravo J, Martinez O, Martinez-Alfaro E, et al. Multicenter study to evaluate the effectiveness and safety of dolutegravir and lamivudine dual therapy in real life (poster). Presented at the XI Congreso Nacional GeSIDA, December 2019, Toledo, Spain.
Postel N, Schneeweiss S, Wyen C, et al. Real-world data from the prospective URBAN cohort study on the use of dolutegravir (DTG) + lamivudine (3TC) in ART-naïve and pre-treated people living with HIV in Germany (Oral presentation). Presented at HIV Drug Therapy Glasgow 2020, October 2020, Virtual.
Bonijoly T, Cabié A, Cheret A, et al. Week-48 efficacy and safety of dolutegravir + rilpivirine dual therapy as a switch strategy in a real-life cohort study (Oral presentation). Presented at the 16th European AIDS Conference, October 2017, Milan, Italy.
Casado JL, Monsalvo M, Fontecha M, et al. Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected patients in a clinical setting. HIV Res Clin Pract. 2019 Apr;20(2):64-72.
Reeves AA, Fuentes AV, Caballero J, Thomas JE, Mosley JF, Harrington C. Neurotoxicities in the treatment of HIV between dolutegravir, rilpivirine and dolutegravir/rilpivirine: a meta-analysis. Sex Transm Infect. 2021;97(4):261-267.
Jenks JD, Hoenigl MJ. CD4:CD8 ratio and CD8+ cell count for prognosticating mortality in HIV-infected patients on antiretroviral therapy. Lab Precis Med. 2018;3:8.
Masia M, Padilla S, Barber X, et al. Comparative impact of suppressive antiretroviral regimens on the CD4/CD8 T-cell ratio: a cohort study. Medicine (Baltimore). 2016;95(11):e3108.
Santos JR, Saumoy M, Curran A, et al. The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial. Clin Infect Dis. 2015;61(3):403-408.
Menard A, Meddeb L, Tissot-Dupont H, et al. Dolutegravir and weight gain: an unexpected bothering side-effect. Aids. 2017;31:1499-1500.
Bourgi K, Jenkins CA, Rebeiro PF, et al. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. J Int AIDS Soc. 2020;23(4):e25484.
Eckard AR, McComsey GA. Weight gain and integrase inhibitors. Curr Opin Infect Dis. 2020;33:10-19.
Rolle C-P, Berhe M, Singh T, et al. Feasibility, efficacy, and safety of dolutegravir/lamivudine (DTG/3TC) as a first line regimen in a test and treat setting for newly diagnosed people living with HIV (PLWH): 48 week results of the STAT study (Oral Presentation). Presented at the 11th International AIDS Society Conference on HIV Science; July 2021; Virtual.
Calza L, Borderi M, Colangeli V, et al. Short communication: no significant changes in weight and body fat mass in suppressed HIV-infected patients switched to dual combination lamivudine plus Dolutegravir or Raltegravir. AIDS Res Hum Retroviruses. 2021;37(3):204-206.
Ciccullo A, Dusina A, Lassandro AP, Borghetti A, Baldin G, Di Giambenedetto S. No significant changes in body fat mass in virologically suppressed. HIV-Positive Patients Switched to Lamivudine-Dolutegravir AIDS. 2020;34(6):956-957.
Vizcarra P, Vivancos MJ, Pérez-Elías MJ, Moreno A, Casado JL. Weight gain in people living with HIV switched to dual therapy: changes in body fat mass. Aids. 2020;34(1):155-157.
Taramasso L, Bonfanti P, Ricci E, et al. Factors associated with weight gain in people treated with Dolutegravir. Open Forum Infect Dis. 2020;7(6):ofaa195.
Lake JE, Wu K, Bares SH, et al. Risk factors for weight gain following switch to integrase inhibitor–based antiretroviral therapy. Clin Infect Dis. 2020;71(9):e471-e477.
Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71(6):1379-1389.
Lake JE, Trevillyan J. Impact of integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV. Curr Opin HIV AIDS. 2021;16(3):148-151.
Gomez M, Seybold U, Roider J, Härter G, Bogner JR. A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017. Infection. 2019;47(1):95-102.
